Daneman D, Fishman L, Clarson C
Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada.
Clin Invest Med. 1987 Sep;10(5):480-3.
We measured insulin antibody binding in 2 groups of patients: Study 1, 32 children with newly diagnosed IDDM before onset of insulin therapy, and, in 20 of these, 10 days, 1, 3, and 6 months after beginning therapy; and Study 2, 35 children with long-standing IDDM, 20 of whom had free insulin concentrations measured before, and for 2 hours following subcutaneous injection of 0.25 U/kg regular insulin. Almost 35% of new onset subjects had insulin antibody binding above control levels. In those studied prospectively, binding increased significantly with time. Pre-treatment binding did not correlate with later insulin antibody binding nor metabolic control. In Study 1 we have confirmed previous studies showing abnormally high insulin antibody binding in children with IDDM pre-treatment. We have been unable to demonstrate a relationship between this binding and that found 6 months after initiation of therapy. In Study 2, we have shown that insulin antibody binding is not related to either the level of metabolic control or the rate of rise of free insulin levels in children with IDDM.
研究1，32名新诊断的胰岛素依赖型糖尿病（IDDM）患儿，在胰岛素治疗开始前，其中20名患儿在治疗开始后的10天、1个月、3个月和6个月进行检测；研究2，35名长期患IDDM的患儿，其中20名在皮下注射0.25 U/kg常规胰岛素前及注射后2小时检测游离胰岛素浓度。近35%的新发病受试者的胰岛素抗体结合高于对照水平。在那些进行前瞻性研究的受试者中，结合率随时间显著增加。治疗前的结合与后期的胰岛素抗体结合及代谢控制均无相关性。在研究1中，我们证实了之前的研究结果，即IDDM患儿在治疗前胰岛素抗体结合异常高。我们未能证明这种结合与治疗开始6个月后的结合之间存在关联。在研究2中，我们表明，IDDM患儿的胰岛素抗体结合与代谢控制水平或游离胰岛素水平的上升速率均无关。
